APX3330 Promotes Neurorestorative Effects after Stroke in Type One Diabetic Rats by Yan, Tao et al.
      
      
                                                                                                   http://dx.doi.org/10.14336/AD.2017.1130     
 
*Correspondence should be addressed to: Dr. Jieli Chen, Department of Neurology, Henry Ford hospital, Detroit, MI, USA. Email: 
JChen4@hfhs.org 
 
Copyright: © 2017 Yan T et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. 
 
ISSN: 2152-5250                                                                                                                                                                                       453 
                  
 
  
Original Article 
 
APX3330 Promotes Neurorestorative Effects after Stroke 
in Type One Diabetic Rats 
 
Tao Yan1,2, Poornima Venkat2, Michael Chopp2,3, Alex Zacharek2, Peng Yu2, Ruizhuo Ning2,4, 
Xiaoxi Qiao5, Mark R. Kelley6, Jieli Chen2, * 
 
1Gerontology Institute, Neurology, Tianjin Medical University General Hospital, Tianjin Neurological Institute, 
Key Laboratory of Post-Neurotrauma Neurorepair and Regeneration in Central Nervous System, Ministry of 
Education and Tianjin City, Tianjin, China 
2Department of Neurology, Henry Ford hospital, Detroit, MI, USA 
3Department of Physics, Oakland University, Rochester, MI, USA 
4Department of Neurology, First Hospital Harbin, Harbin, China. 
5Department of Ophthalmology, Henry Ford Hospital, Detroit, MI, USA 
6Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA 
 
  [Received October 6, 2017; Revised November 29, 2017; Accepted November 30, 2017] 
 
ABSTRACT: APX3330 is a selective inhibitor of APE1/Ref-1 redox activity. In this study, we investigate the 
therapeutic effects and underlying mechanisms of APX3330 treatment in type one diabetes mellitus (T1DM) 
stroke rats.  Adult male Wistar rats were induced with T1DM and subjected to transient middle cerebral artery 
occlusion (MCAo) and treated with either PBS or APX3330 (10mg/kg, oral gavage) starting at 24h after MCAo, 
and daily for 14 days. Rats were sacrificed at 14 days after MCAo and, blood brain barrier (BBB) permeability, 
ischemic lesion volume, immunohistochemistry, cell death assay, Western blot, real time PCR, and angiogenic 
ELISA array were performed. Compared to PBS treatment, APX3330 treatment of stroke in T1DM rats 
significantly improves neurological functional outcome, decreases lesion volume, and improves BBB integrity as 
well as decreases total vessel density and VEGF expression, while significantly increases arterial density in the 
ischemic border zone (IBZ). APX3330 significantly increases myelin density, oligodendrocyte number, 
oligodendrocyte progenitor cell number, synaptic protein expression, and induces M2 macrophage polarization 
in the IBZ of T1DM stroke rats. Compared to PBS treatment, APX3330 treatment significantly decreases 
plasminogen activator inhibitor type-1 (PAI-1), monocyte chemotactic protein-1 and matrix metalloproteinase 9 
(MMP9) and receptor for advanced glycation endproducts expression in the ischemic brain of T1DM stroke rats. 
APX3330 treatment significantly decreases cell death and MMP9 and PAI-1 gene expression in cultured primary 
cortical neurons subjected to high glucose and oxygen glucose deprivation, compared to untreated control cells. 
APX3330 treatment increases M2 macrophage polarization and decreases inflammatory factor expression in the 
ischemic brain as well as promotes neuroprotective and neurorestorative effects after stroke in T1DM rats. 
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Hyperglycemia and insulin resistance are major risk 
factors for ischemic stroke, atherosclerosis, and vascular 
and cardiac complications [1]. Diabetes mellitus (DM) 
instigates a cascade of events which lead to vascular 
endothelial cell dysfunction, increased vascular 
permeability, a disequilibrium of angiogenesis, and poor 
recovery after ischemic stroke [2, 3]. Both stroke and 
diabetes cause extensive damage to white matter (WM) [4, 
5] which can potentially lead to long term disability due 
to the brain’s limited capacity of axonal regeneration, and 
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an unfavorable environment for axon regrowth, sprouting 
and remyelination in the ischemic brain [6]. Therefore, in 
addition to neuroprotection in the gray matter, therapies 
that protect WM and promote WM remodeling after 
stroke, will enable long term neurological functional 
recovery via strengthening residual neuronal connections, 
forging new connections, and axonal rewiring in the 
injured brain [7]. Approximately 30% of all stroke 
patients suffering from diabetes, battle worse prognosis at 
least in part due to high inflammation and exacerbated 
WM injury in the ischemic diabetic brain. Hence, there is 
a critical need to develop therapeutic strategies 
specifically to improve neurological functional outcome 
after stroke in the DM population. 
In diabetic stroke, exacerbated blood brain barrier 
(BBB) disruption and inflammation are key factors that 
contribute to poor outcome [4, 8, 9]. Matrix 
metalloproteinases (MMP) are associated with BBB 
disruption, and known to aggravate WM injury [4, 8, 9]. 
Myelin degradation following ischemic stroke is 
attenuated in MMP9 knockout mice [10], implicating 
MMP’s in post-stroke WM injury. Inflammatory factors 
such as the receptor for advanced glycation endproducts 
(RAGE) play a vital role in promoting inflammation and 
diabetic complications [11, 12]. In our previous study, we 
have reported that RAGE is increased in diabetic stroke 
animals [13]. Increased RAGE expression has been 
implicated in promoting inflammation in the ischemic 
brain, and has been associated with neurological deficits 
in DM animals after stroke [13]. A permeable BBB 
facilitates the infiltration of peripheral macrophages into 
the ischemic brain [14, 15], and these macrophages 
initially assume an anti-inflammatory M2 phenotype and 
aid in clearing cellular debris from the injured brain [16, 
17]. These macrophages can also assume/transition into a 
neurodegenerative M1 phenotype and hinder recovery by 
releasing proinflammatory factors. These pro-
inflammatory molecules can in turn worsen BBB damage, 
initiate the recruitment of peripheral immune cells into the 
cerebral microcirculation and ischemic brain, as well as 
induce systemic inflammation [18]. Therefore, in diabetic 
subjects, it is important to control post stroke 
inflammatory responses and extend the M2 phase of 
macrophages and delay their transition into the pro-
inflammatory M1 phenotype in to improve stroke 
outcome.   
APX3330 is a small molecule inhibitor of apurinic 
apyrimidinic endonuclease redox effector factor-1 
(APE1/Ref-1) redox activity [19]. Alterations in the 
expression, subcellular localization and activity of 
APE/Ref-1 have been associated with several diseases 
such as neurodegeneration, cancer and cardiovascular 
diseases. The role of APE1/Ref-1 in disease pathology and 
its potential as a novel therapeutic target has been 
reviewed elsewhere [19-21]. Several studies have 
demonstrated the specificity of APX3330 for APE1 [19]. 
APE1 activates nuclear factor kappa B (NFκB) and 
hypoxia-inducible factor 1α (HIF-1α), which are involved 
in apoptosis, inflammation and angiogenesis [20, 22]. 
NFκB is induced in neurons following stroke and is a key 
mediator of inflammatory responses and infarction 
development/expansion after stroke [23]. NFκB is also 
known to critically regulate resident inflammatory brain 
cells and microglia that are activated in response to 
ischemic injury [24]. In T1DM stroke rats, suppressing 
NFκB signaling pathway significantly decreases 
inflammatory factors such as RAGE and TLR4 expression 
in the ischemic brain and improves stroke outcome [25]. 
HIF-1α is a transcriptional activator that maintains 
oxygen homeostasis and functions as a master regulator 
of tissue responses to hypoxic conditions. While 
neuroprotective therapies that up regulate HIF-1α activity 
have been reported to promote pro-angiogenic responses 
and improve stroke outcome in diabetic mice [26], several 
reports also indicate that DM up regulates HIF-1α protein 
levels and increases HIF-1α transcriptional activity in 
endothelial cells, which in turn can adversely affect tight 
junction proteins and BBB permeability [27, 28]. DM 
drives increased but dysfunctional neovascularization in 
the cerebrovasculature, which upon ischemic stress can 
become leaky and disrupt/aggravate BBB rupture [29]. 
Hypoxia stimulates angiogenesis mainly via activation of 
HIF-1α and vascular endothelial growth factor (VEGF). 
In T1DM stroke rats, an abnormal and persistent increase 
in VEGF correlated with increased BBB permeability in 
the ischemic brain [30], and inhibiting VEGF improved 
tight junction proteins and decreased endothelial leakage 
i.e. BBB leakage [28].  
APX3330 inhibits NFκB and HIF-1α activity [31], 
and can potentially attenuate neuroinflammatory 
responses and post ischemic angiogenesis, which makes 
APX3330 a suitable candidate for stroke therapy in DM 
rats. In this study, we are the first to investigate whether 
APX330 treatment could improve functional outcome 
after stroke in Type one diabetic (T1DM) rats, whether 
APX3330 induces neurorestorative effects, and what 
mechanisms are involved in APX330 treatment induced 
beneficial effects in T1DM stroke rats.  
 
MATERIALS AND METHODS 
 
All experiments followed the standards of the American 
Council on Animal Care and Institutional Animal Care 
and Use Committee of Henry Ford Health System. 
 
T1DM induction 
 
Adult male Wistar rats (225-250g, Jackson Laboratory) 
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were induced with T1DM using a single intraperitoneal 
injection of Streptozotocin (STZ, 60 mg/kg) [32]. After 2 
weeks, rats with fasting blood glucose >300 mg/dl were 
defined as T1DM and included in the study.  
 
Middle cerebral artery occlusion (MCAo) model and 
experimental groups 
 
T1DM rats were anesthetized with 2% isoflurane in a 
chamber for pre-anesthetic, and spontaneously respired 
with 1.5% isoflurane in 2:1 N2O:O2 mixture using a 
facemask connected and regulated with a modified 
FLUOTEC 3 Vaporizer (Fraser Harlake). Rectal 
temperature was maintained at 37oC throughout the 
surgical procedure using a feedback regulated water 
heating system. T1DM rats were subject to transient (2 
hour) MCAo via intraluminal vascular occlusion as 
previously described [33, 34]. T1DM stroke rats were 
randomized (n=7/group) and treated with phosphate 
buffered saline (PBS-vehicle control) or APX3330 (10 
mg/kg, gavage) initiated at 24 hours after MCAo daily for 
14 days. Rats were sacrificed at 14 days after MCAo for 
immunostaining quantification analysis.  
 
Functional tests 
 
An investigator blinded to the experimental groups 
performed a battery of functional tests including the 
modified neurological severity score and foot-fault tests 
prior to MCAo, and on days 1, 7 and 14 after MCAo, as 
previously described [35]. The modified neurological 
severity score is a composite of motor, sensory, reflex and 
balance tests, with scores ranging between 0 (no deficit) 
to 18 (maximum deficit). Hence, a higher score indicates 
greater neurological severity. Rats with scores <6 
(possibly small to no lesion, their condition improves 
regardless of treatment) and >13 (very large lesion, poor 
survival, their condition deteriorates regardless of 
treatment) were excluded before treatment. The foot-fault 
test is routinely employed to evaluate sensorimotor 
function, motor coordination and limb placement deficits 
during locomotion [36]. The rats were placed on a 2.5 cm 
× 2.5 cm grid floor (45 cm × 30 cm) placed 2.5 cm above 
the base floor. A foot-fault was defined as a fall or slip 
through a grid opening due to an inaccurate forelimb 
placement. Data are presented as the percentage of foot-
faults of the left paw over a 100-forelimb movement. 
 
Immunohistochemical assessment 
 
All animals were transcardially perfused with 0.9% saline, 
and brains were rapidly removed, and immersion fixed in 
4% paraformaldehyde and then embedded in paraffin. 
Seven coronal brain sections were processed and a series 
of 6 μm thick sections were cut from blocks which were 
obtained from the center of the lesion (bregma -1 mm to 
+1 mm). Every 10th coronal section for a total of 5 sections 
was used for immunohistochemical staining. 
Hematoxylin and Eosin (H&E) staining was used for 
ischemic lesion volume calculation and presented as a 
percentage of the lesion compared with the contralateral 
hemisphere [37]. Antibody against α-smooth muscle actin 
(αSMA, smooth muscle cell marker, mouse monoclonal 
IgG 1:800, Dako), Von Willebrand Factor (vWF, an 
endothelial cell marker, 1:400; Dako), VEGF (1:50, Santa 
Cruz), synaptophysin (synaptic protein marker, 1:500, 
Chemicon), neuron-glial antigen 2 (NG2, 
oligodendrocyte progenitor cell marker, 1:800, Chemicon) 
and 2',3'-cyclic-nucleotide 3'-phosphodiesterase (CNPase, 
oligodendrocyte marker, 1:200, Chemicon), ED1 
(microglia/macrophages marker, 1:30; AbD Serotec), and 
CD163 (M2 macrophage marker, 1:500, Abcam) were 
employed. FITC-Albumin (1:500, Abcam) staining was 
employed to evaluate BBB permeability, and Luxol fast 
blue (LFB) staining was used to demonstrate myelin. In 
control experiments, primary antibody was replaced by 
non-immune serum.  
 
Quantification analysis 
 
An investigator blinded to the experimental groups 
performed all immunostaining quantification analysis. 
Five slides from each brain (each slide containing 8 fields 
from striatum of the ischemic boundary zone (IBZ)) were 
digitized under a 20× objective (Olympus BX40) using a 
3-CCD color video camera (Sony DXC-970MD) 
interfaced with an MCID image analysis system (Imaging 
Research). The number of arteries stained with αSMA 
were counted and analyzed with regard to small and large 
vessels (≥10μm diameter). For other immunostaining 
measurements, positive cell numbers were counted for 
each field of view or the positive stained areas were 
measured using the densitometry function (MCID image 
analysis system) with a density threshold above unstained 
set uniformly for all groups [38-40]. 
 
Angiogenic ELISA array 
 
An additional set of rats (n=4/group) were sacrificed at 14 
days after MCAo and brain tissue was extracted from the 
ischemic brain for angiogenic ELISA assays and Western 
blot assays. An angiogenesis array kit (R&D Systems, 
mouse angiogensis array kit) was used to simultaneously 
assess the relative levels of angiogenesis-related proteins 
in ischemic brain tissue which had been treated with or 
without APX3330. Briefly, samples were mixed with 
detection antibodies for 1 hour at room temperature and 
added to the array membrane. Then, the membranes were 
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incubated over night at 2-8°C on a shaker. Following a 
washing step, horseradish peroxidase-conjugated 
streptavidin was added and incubated for 30 minutes. 
After washing, X-ray film and ImageJ analysis software 
were used to quantify array signals. 
 
Western blot assay 
 
Equal amounts of cell lysate were subjected to Western 
blot analysis which was performed as previously 
described [41]. Specific proteins were visualized using a 
Super Signal West Pico chemiluminescence kit (Pierce). 
Protein concentration was measured using the BCA kit 
(Thermo Scientific). The following primary antibodies 
were used: anti-β-actin (1:2000; Santa Cruz 
Biotechnology), anti-MMP9 (1:500; Santa Cruz 
Biotechnology) and anti-RAGE (1:500, R&D 
Biosystems). 
 
Primary cortical neuron (PCN) culture 
 
PCNs were harvested from pregnant (day 18) embryonic 
Wistar rats (Charles River). The cultures were prepared as 
previously described with some modifications [42, 43]. 
Briefly, the embryo cerebral cortex was dissected and 
dissociated in Ca2+ and Mg2+ free HBSS with 0.125% 
trypsin. The cells were placed on poly-d-lysine (Sigma) 
coated dishes (35 mm, Corning) and initially cultured in 
DMEM media (Life Technologies) with 5% fetal bovine 
serum for 5 hours, then neurobasal growth medium (Life 
Technologies) with 2% B-27 (Life Technologies), 2 mM 
GlutaMax, and 1% antibiotic-antimycotic was used. 
 
 
 
 
 
Figure 1. APX3330 improves stroke outcome and decreases ischemic burden and BBB permeability in 
T1DM rats.  Treatment with APX3330 significantly improves neurological functional outcome after stroke in 
T1DM rats as indicated by (A) Foot-fault test and (B) modified neurological severity score (mNSS). APX3330 
treatment also significantly decreases (C) ischemic lesion volume and (D) BBB disruption after stroke in T1DM 
rats.  
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High glucose and oxygen glucose deprivation (OGD) 
conditions 
 
To subject cells cultures to OGD, serum and glucose free 
media was used. Cells were placed in a hypoxia chamber 
(Forma Anaerobic System; Thermo Scientific) with 37°C 
incubator for 2 hours. After 2 hours, the cells were 
removed and replaced in high glucose cultured media 
(37.5 µM). 
 
Lactate dehydrogenase (LDH) assay 
 
The CytoTox 96 non-radioactive cytotoxicity assay kit 
(Promega) was used following standard protocol. Briefly, 
cells were cultured in a 96 well plate for 24 hours and then 
the cells in half the wells for each experimental group 
were lysed to give total LDH, while media only was 
collected from the other set of wells for secreted LDH. 
The media was added to a fresh 96 well plate, followed by 
the addition of substrate solution. Following incubation, 
absorbance was recorded at 490 nm.  
 
MTS assay 
 
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy-methoxy-
phenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay 
was performed using CellTiter 96 Aqueous One Solution 
Cell Proliferation Assay (Promega). 5000 cells were 
plated and 20 μL MTS was added to each well and 
incubated after treatment. Absorbance was recorded at 
490 nm. 
 
Statistical analysis 
 
All measurements and analyses were performed by 
normality of distribution. One-way Analysis of Variance 
(ANOVA) was used for the evaluation of functional tests, 
immunostaining, respectively. “Contrast/estimate” 
statement was used to test the group difference. All data 
are presented as mean ± standard error (SE). 
 
 
 
 
Figure 2.  APX3330 increases arterial density and decreases dysfunctional angiogenesis after stroke in 
T1DM rats. APX3330 significantly increases (A) arterial density and decreases (B) vascular density and (C) 
VEGF expression in the ischemic border zone after stroke in T1DM rats, as indicated by α-smooth muscle actin 
(α-SMA), Von Willebrand Factor (vWF) and vascular endothelial growth factor (VEGF) immunostaining and 
quantification data respectively.    
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Figure 3. APX3330 significantly promotes white matter remodeling after stroke in T1DM rats. APX3330 significantly 
increases (A) myelin density (Luxol fast blue), (B) synaptic protein expression (Synaptophysin), (C) oligodendrocyte cell number 
(CNPase), and (D) oligodendrocyte progenitor cell (NG2) number in the ischemic border zone of T1DM stroke rats. 
 
 
RESULTS  
 
APX3330 treatment significantly improves neurological 
outcome, and decreases lesion volume and BBB 
permeability after stroke in T1DM rats 
 
To evaluate the therapeutic effects of APX3330 treatment 
in T1DM stroke rats, mNSS and foot-fault tests were used 
to evaluate neurological function. APX3330 treatment 
significantly improves functional outcome after stroke in 
T1DM rats and the data show that the overall group effect 
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was significant on day 14 after stroke (p<0.05, n=7/group, 
Fig. 1A-B). APX3330 significantly decreases ischemic 
lesion volume (p<0.05, n=7/group, Fig. 1C) and decreases 
BBB leakage (p<0.05, n=7/group, Fig. 1D) compared to 
PBS treated control T1DM stroke rats.  
  
APX3330 treatment decreases dysfunctional 
angiogenesis and VEGF expression in T1DM stroke rats 
 
To test whether APX3330 treatment regulates post stroke 
angiogenesis, vascular and arterial density was measured 
in the IBZ. Figure 2A shows that APX3330 significantly 
increases arterial density (p<0.05, n=7/group) compared 
to PBS treated control T1DM stroke rats. However, total 
vascular density was significantly reduced in APX3330 
treatment rats compared with PBS treated control T1DM 
stroke rats (p<0.05, n=7/group, Fig. 2B). APX3330 also 
significantly decreases VEGF expression in the IBZ 
(p<0.05, n=7/group, Fig. 2C) compared to PBS treated 
control T1DM stroke rats. 
 
APX3330 treatment significantly promotes WM and 
axonal remodeling after stroke in T1DM rats 
 
To test whether APX3330 treatment regulates WM and 
axonal remodeling, Luxol fast blue (myelin density) and 
Synaptophysin (synaptic protein expression) expression 
were quantified in the IBZ. APX3330 significantly 
promotes myelin density (p<0.05, n=7/group, Fig. 3A) 
and synaptophysin expression (p<0.05, n=7/group, Fig. 
3B) in the IBZ compared to PBS treated control T1DM 
stroke rats. APX3330 treatment also significantly 
increases oligodendrocyte (CNPase, p<0.05, n=7/group, 
Fig. 3C) and oligodendrocyte progenitor cell density 
(NG2, p<0.05, n=7/group, Fig. 3D) in the IBZ compared 
to PBS treated control T1DM stroke rats.  
 
 
 
 
Figure 4. APX3330 treatment significantly promotes M2 macrophage polarization in the ischemic brain of T1DM stroke 
rats. APX3330 significantly decreases (A) ED1 (M1 macrophage marker, and significantly increases (B) CD163 (M2 
macrophage marker) in the ischemic border zone of T1DM stroke rats. 
 
APX3330 treatment significantly decreases 
inflammatory factor expression after stroke in T1DM 
rats 
 
To investigate mechanisms of APX3330 induced 
neuroprotective and neurorestorative effects in T1DM 
stroke, we evaluated inflammatory factor expression in 
the ischemic brain. APX3330 treatment significantly 
promotes M2 macrophage polarization as indicated by 
decreased ED1 (M1 macrophage marker) and increased 
CD163 (M2 macrophage marker) in the IBZ of T1DM 
stroke rats (p<0.05, n=7/group, Fig. 4A-B). Angiogenic 
ELISA assay (Fig. 5A) shows that APX3330 decreases 
plasminogen activator inhibitor type 1 (PAI-1, 5-fold, Fig. 
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5B), monocyte chemotactic protein-1 (MCP1, 3-fold, Fig. 
5C) and MMP9 (3-fold, Fig. 5D) compared to T1DM-
MCAo control rats. We also measured the ischemic brain 
expression level of MMP9 and RAGE by Western blot. 
APX3330 significantly decreases ischemic brain tissue 
expression of MMP9 and RAGE compared to PBS treated 
control T1DM stroke rats (p<0.001, n=4/group, Fig. 6A). 
These data indicate that APX3330 treatment decreases 
inflammatory factor and pro-thrombotic factor expression 
in the ischemic brain after stroke in T1DM rats.  
 
 
 
 
Figure 5. APX3330 treatment significantly decreases inflammatory factors after stroke in T1DM rats. (A) An ELISA array 
was employed to measure inflammatory protein expression in the ischemic brain. APX3330 significantly decreases (B) 
plasminogen activator inhibitor type 1 (PAI-1), (C) monocyte chemotactic protein-1 (MCP1) and (D) MMP9 compared to control 
T1DM stroke rats. 
 
APX3330 significantly decreases cell death and 
inflammatory factor gene expression in primary cortical 
neurons subjected to high glucose and OGD conditions 
 
To test the effects of APX3330 on primary cortical 
neurons cell death and proliferation, LDH and MTS 
assays were performed. APX3330 treatment does not 
increase primary cortical neuron proliferation, but 
significantly decreases cell death compared to control 
(untreated) cells as measured by MTS (data not shown) 
and LDH (Fig. 6B) assays, respectively, which is 
consistent with the myelin protective effect observed in 
vivo. APX3330 treatment significantly decreases MMP9 
and PAI-1 gene expression in primary cortical neurons 
subjected to high glucose and oxygen glucose deprivation, 
when compared to control (untreated) cells (Fig. 6C).  
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Figure 6. APX3330 treatment decreases inflammatory factor expression in the ischemic brain of T1DM stroke rats 
and significantly decreases primary cortical neurons cell death and inflammatory factor expression after stroke. 
(A) Western blot assay shows that APX3330 significantly decreases ischemic brain tissue expression of MMP9 and RAGE 
compared to control T1DM stroke rats. APX3330 treatment significantly decreases (B) primary cortical neuron cell death 
compared to control (untreated) cells as measured by LDH assay and (C) significantly decreases MMP9 and PAI-1 gene 
expression in primary cortical neurons subjected to high glucose and oxygen glucose deprivation, when compared to 
control (untreated) cells.  
 
DISCUSSION 
 
In this study, we are the first to demonstrate that APX3330 
treatment significantly improves neurological functional 
outcome and decreases lesion volume and BBB 
permeability after stroke in T1DM rats. APX3330 
promotes WM remodeling and exerts myelin protective 
effects in the IBZ of T1DM stroke rats. By employing an 
angiogenic ELISA assay and Western blot analysis, we 
also confirmed that APX3330 treatment significantly 
decreases the expression of inflammatory factors such as 
MCP1, MMP9 and RAGE and pro-thrombotic factor PAI-
1, in the ischemic brain of T1DM stroke rats. APX3330 
significantly decreases gene expression of inflammatory 
factor MMP9 and pro-thrombotic PAI-1 in cultured 
primary cortical neurons subjected to high glucose and 
oxygen glucose deprivation conditions. These data 
indicate that APX3330 may be a novel treatment for 
T1DM stroke. 
DM stroke induces extensive vascular damage, and 
our previous study has shown that there is a significant 
increase in vascular density in the ischemic border zone 
after stroke in T1DM rats compared to wild type non-DM 
rats [44]. However, the increase in vascular density is 
often an increase in non-functional blood vessels that 
contribute to brain hemorrhage and worse functional 
outcome after stroke [44]. Our present study shows that 
APX3330 treatment significantly increases arterial 
density but decreases total vascular density, indicating the 
potential of APX3330 to reverse DM stroke induced 
growth of unnecessary and non-functional blood vessels. 
BBB function is widely attributed to proper function and 
integrity of endothelial cells, tight junction protein and 
pericytes [45]. Aggravated BBB disruption has been 
demonstrated in T1DM stroke rats compared to non-DM 
stroke rats [44]. Protecting/improving BBB integrity is 
important for recovery after stroke, and we found that 
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APX3330 decreases BBB leakage compared to control 
T1DM stroke rats.  
In addition to massive vascular destruction, DM 
stroke also induces significant damage to the WM in the 
ischemic brain. Extensive WM after stroke has been 
associated with greater mortality, worse neuronal 
dysfunction and greater residual sensory-motor deficits 
after DM stroke [5, 46-48]. Promoting WM remodeling 
essentially initiates rewiring of the neural circuits thereby 
improving intercellular connectivity and communication. 
Since APX3330 significantly improves neurological 
function after stroke in T1DM rats, we investigated 
APX3330 effect on WM remodeling. Our data show that 
APX3330 significantly increases myelin density in the 
ischemic border zone of T1DM stroke rats compared to 
control T1DM stroke rats. In the central nervous system, 
oligodendrocyte and oligodendrocyte progenitor cells 
form myelin and exert crucial roles in WM function and 
homeostasis [49]. In several neurological diseases 
including stroke, WM damaged has been associated with 
oligovascular uncoupling [49]. Therefore, maintenance/ 
increase of oligodendrocytes and oligodendrocyte 
progenitor cells number may contribute to WM recovery 
and decrease neurological functional deficits [49-51]. We 
found that APX3330 treatment in T1DM stroke rats 
significantly increases the number of oligodendrocytes 
and oligodendrocyte progenitor cells in the ischemic 
border zone, which may contribute to functional recovery 
after stroke in T1DM rats. Taken together, it is most likely 
that APX3330 improves neurological functional outcome 
via promoting WM remodeling after stroke in T1DM rats. 
Neuroinflammatory responses play an important 
role in post-stroke recovery. While mild to moderate 
inflammation can be beneficial to brain repair, 
uncontrolled inflammation can create an inhospitable 
environment for brain repair and hinder/worsen recovery 
[7, 52]. In our study, Western blot analysis and an 
angiogenic ELISA array show that APX3330 treatment 
significantly decreases inflammatory factors such as 
MCP1, MMP9 and RAGE compared to control T1DM 
stroke rats. APX3330 also significantly decreases MMP9 
and PAI-1 gene expression in cultured primary cortical 
neurons subjected to high glucose and OGD conditions. 
Both in-vivo after ischemic stroke and in-vitro using OGD 
model of stroke with primary rat cortical neurons, it has 
been reported that MMP9 is activated and expressed in 
neuronal nuclei and associated with delayed neuronal 
death [53]. Other studies have also reported that MMP9 
inhibition in cultured primary cortical neurons subject to 
OGD decreases apoptosis and induces neuroprotective 
effects [54]. DM is associated with diminished 
fibrinolytic capacity, increased coagulability and 
increased PAI-1 concentration in blood [55]. Increased 
PAI-1 levels in the DM population can cause formation of 
intravascular thrombi and atherosclerotic lesions which in 
turn can cause stroke [56, 57]. Increased PAI-1 levels can 
trigger several cytokines and chemokines, and promote 
pro-inflammatory responses [58]. In addition, 
proinflammatory cytokines can disturb vascular 
endothelial function and increase PAI-1 level [59]. 
Elevated PAI-1 levels has also been suggested to be a true 
indicator of metabolic syndrome [59]. DM patients also 
have elevated MCP levels [60], which has been implicated 
in DM induced vascular calcification and diabetic 
nephropathy [61, 62]. Rats with nonfunctional MCP1 
have smaller infarct volume and lesser macrophage 
infiltration post stroke, which suggests that attenuation of 
MCP1 may exert neuroprotective effects [63]. 
Inflammatory factors such as MMP9 and RAGE are 
typically increased in diabetic stroke animals [13]. In 
addition to regulating post stroke inflammatory responses, 
MMP9 also plays an important role in post stroke 
angiogenesis and BBB disruption [5, 64]. Increased 
MMP9 expression in the acute phase of stroke in DM 
patients creates a pro-inflammatory state that worsens 
WM damage. Neuroinflammation plays a major role in 
WM damage and oligodendrocyte death, in particular 
increased MMP9 expression has been associated with 
myelin breakdown [65, 66]. RAGE, as a proinflammatory 
factor, plays a critical role in neurodegenerative pathology, 
necrotic cell death and inflammatory responses [67]. The 
RAGE signaling pathway is involved in numerous 
pathological process following ischemia, such as 
inflammation, vascular injury, and brain damage [68, 69]. 
Our previous studies have implicated increased RAGE 
expression in worsening the outcome of DM stroke [13]. 
In this study, we found that APX3330 significantly 
decreases PAI-1, MCP-1, MMP9 and RAGE levels in the 
ischemic brain which may contribute to APX3330 
induced neuroprotective and neurorestorative effects in 
T1DM stroke rats.  
Following ischemic injury, macrophages promote 
both injury and repair depending on their phenotype. M2 
macrophage polarization is a potential target for stroke 
therapy since anti inflammatory M2 macrophages exert 
neuroprotection, improve neuronal survival and decrease 
the expression of inflammatory factors in the ischemic 
brain [17, 70]. M2 macrophage polarization has been 
associated with improved functional recovery after stroke 
[71], as well as decreased neuroinflammation and 
enhanced axon growth in injured mouse spinal cord [72]. 
APX3330 promotes M2 macrophage polarization, marked 
by increased M2 macrophage marker CD163 and 
decreased M1 macrophage marker, ED1 expression in the 
IBZ of T1DM stroke rats. MCP-1 is a chemokine that 
regulates the migration and infiltration of macrophages in 
pathological tissue [73], and MCP-1-deficient mice 
subjected to stroke exhibit a reduction of phagocytic 
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macrophage accumulation in the infarcted brain tissue 
[74]. Macrophage differentiation into proinflammatory 
M1 phenotype is mediated at least in part by RAGE/NF-
κB pathway activation [75]. M1 Macrophages (in addition 
to monocytes and leukocytes) are a prolific source of 
inflammatory factors like MMP9 [76]. Therefore, it is 
likely that APX3330 induced attenuation of MCP-1 and 
RAGE/NF-κB pathway decreases M1 macrophage and 
promotes M2 macrophage polarization, which then in turn 
decreases neuroinflammatory factor production. However, 
the interconnections between M2 polarization and 
APX3330 induced regulation of neuroinflammation and 
WM remodeling leading to beneficial effects after stroke 
in T1DM rats are not completely understood and further 
studies are warranted. 
We acknowledge that APX3330 may have 
conflicting results in DM versus non-DM stroke. For 
instance, using an APE1 conditional knockout mouse line, 
it has been recently demonstrated that the deletion of 
APE1 significantly increases ischemic lesion volume, 
worsens neurological functional recovery, impairs 
neuronal communication and aggravates demyelination as 
well as neuronal and oligodendrocyte degeneration in 
non-DM mice subjected to stroke [77]. However, the 
present study shows that APE1/Ref-1 redox inhibition via 
APX3330 treatment in DM stroke rats exerts 
neuroprotective and neurorestorative effects. These 
differences could be attributed at least in part to the role 
of VEGF signaling which differs between DM and non-
DM stroke [30]. A robust increase in VEGF post ischemic 
injury to the brain correlated with aggravated BBB 
disruption in DM stroke mice [30]. Attenuation of VEGF 
after stroke significantly decreased BBB permeability, 
prevented the loss of synaptic structure in the IBZ, and 
promoted neurological functional recovery after stroke in 
DM mice, however, in non-DM stroke mice; attenuation 
of VEGF had adverse effects [30]. It has been previously 
demonstrated that in the acute phase of stroke in non-DM 
rodents, administration of VEGF enhances cerebral 
microvascular perfusion, increases BBB leakage, induces 
cerebral hemorrhage and expands infarction volume after 
stroke [78]. Our previous study has reported that at 1 day 
after stroke, VEGF is significantly increased in the 
ischemic brain of DM rats compared to non-DM rats [79]. 
Therefore, particularly in DM stroke, VEGF signaling can 
potentially induce extensive vascular damage [80, 81]. In 
this study, our data indicate that APX3330 decreases 
VEGF expression in the IBZ compared to control T1DM 
stroke rats. Since APE1/Ref-1 redox inhibition can affect 
multiple signaling pathways including VEGF, effects of 
APX3330 are likely to be different in DM stroke 
compared to non-DM stroke and further studies are 
warranted.          
While the molecular mechanisms of APX3330 
induced neuroprotective and neurorestorative effects in 
T1DM stroke rats are still unclear, this proof-of-concept 
study shows that APX3330 can significantly improve 
neurological functional outcome, decrease lesion volume, 
decrease BBB permeability, regulate inflammatory 
responses and promote white matter remodeling after 
stroke in T1DM rats.     
 
Conclusions 
 
APX3330 treatment of stroke significantly improves 
neurological functional outcome and decreases ischemic 
lesion volume and BBB permeability in T1DM rats. 
APX3330 treatment significantly decreases VEGF, PAI-1, 
RAGE, MCP1 and MMP9 levels in ischemic brain which 
may contribute to decreasing dysfunctional angiogenesis, 
inflammation in T1DM stroke rats. APX3330 
significantly increases myelin density, oligo-
dendrogenesis and synaptic plasticity after stroke in 
T1DM rats. Therefore, APX3330 treatment derived 
neuroprotective and neurorestorative effects in T1DM 
stroke rats may be attributed at least in part to attenuation 
of dysfunctional angiogenesis, decrease in pro-
inflammatory factors and increased white matter 
remodeling.  
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